# Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

> **NCT06712355** · PHASE3 · RECRUITING · sponsor: **BioNTech SE** · enrollment: 621 (estimated)

## Conditions studied

- Extensive-stage Small-cell Lung Cancer

## Interventions

- **DRUG:** Pumitamig
- **DRUG:** Atezolizumab
- **DRUG:** Etoposide
- **DRUG:** Carboplatin (or cisplatin if carboplatin is not tolerated)

## Key facts

- **NCT ID:** NCT06712355
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-03
- **Primary completion:** 2028-12
- **Final completion:** 2029-03
- **Target enrollment:** 621 (ESTIMATED)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06712355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06712355, "Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06712355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*